Variables | Patients with renal involvement (n = 287) | Patients without renal involvement (n = 62) | p-value |
Age (years) | 64.2 ± 12.2 | 60.7 ± 14.8 | 0.045 |
Gender (M/F) | 133/154 | 32/30 | 0.451 |
MPO-positive AAV | 262 (91.3%) | 54 (87.1%) | 0.306 |
PR3-positive AAV | 25 (8.7%) | 8 (12.9%) |
|
General manifestation | 192 (66.9%) | 50 (80.7%) | 0.033 |
Skin involvement | 17 (5.9%) | 5 (8.1%) | 0.733 |
ENT involvement | 8 (2.8%) | 7 (11.3%) | 0.008 |
Cardiovascular involvement | 105 (36.6%) | 7 (11.3%) | <0.001 |
Abdominal involvement | 92 (32.1%) | 8 (12.9%) | 0.002 |
Nervous system involvement | 28 (9.8%) | 11 (17.7%) | 0.07 |
Pulmonary involvement | 127 (44.3%) | 37 (59.7%) | 0.027 |
Alveolar hemorrhage | 41 (14.3%) | 7 (11.3%) | 0.535 |
Interstitial lung disease | 77 (26.8%) | 25 (40.3%) | 0.034 |
Hemoglobin (g/L) | 87.0 (73.0, 105.0) | 108.5 (95.8, 121.3) | <0.001 |
Serum albumin (g/L) | 29.0 (26.0, 35.0) | 33.0 (29.8, 37.0) | <0.001 |
Complement C3 (g/L) | 0.78 (0.64, 0.89) | 0.92 (0.79, 1.14) | <0.001 |
Complement C4 (g/L) | 0.22 (0.17, 0.27) | 0.23 (0.16, 0.28) | 0.963 |
BVAS | 15.0 (12.0, 19.0) | 9.0 (8.0, 12.0) | <0.001 |
Survival | 147 (54.7%) | 38 (70.4%) | 0.033 |
Death | 122 (45.4%) | 16 (29.6%) |
|